Company · Healthcare
Paediatric respiratory research to prevent childhood lung disease
Every investor coverage indicates participated in a round Wal-yan Respiratory Research Centre raised.
Companies Wal-yan Respiratory Research Centre acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Barry Clements | Paediatric Respiratory Clinician | Brandon Capital, Brandon BioCatalyst |
Stories naming Wal-yan Respiratory Research Centre. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A Telethon Kids spin-out backed by Brandon Capital has begun trials in the US and Australia of RSP-1502, an inhaled antibiotic booster for cystic fibrosis lung infections, after strong early results in WA patients.
A Telethon Kids offshoot, Respirion Pharmaceuticals, is trialling its antibiotic-booster therapy RSP-1502 in the US and Australia, with backing from Brandon Capital and an American cystic fibrosis foundation.